We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Theracryf Plc | TCF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -4.55% | 1.05 | 08:25:15 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.10 | 1.05 | 1.10 | 1.05 | 1.10 |
| Industry Sector |
|---|
| EQUITY INVESTMENT INSTRUMENTS |
| Top Posts |
|---|
Posted at 07/1/2025 22:45 by thiopia Comparing TCF and PYC for upside potentialTCF - Theracryf PYC - Physiomics TCF - share price 0.75p Mkt Cap £3m PYC - share price 0.75p Mkt Cap £1.5m 52 week high as of (Jan 2025) TCF - 1.85p PYC - 1.85p Charting w.r.t 50/200 day Moving Averages TCF is currently above the 50 and 200 day Moving Averages PYC is currently in between narrowing 50 and 200 Moving Averages Potential Catalysts ? PYC - consulting contracts ? software/IP development with partners such as DoseMeRX / Beyond Blood Diagnostics ? Government grants to run NHS trials ? TCF - has an existing $160m deal with Stalicla where a $0.5m milestone payment has been due/overdue for 12 months and another $5m milestone could be imminent for their Autism candidate. TCF claim to be in amicable discussions with Stalicla to resolve this issue. $0.5m would be very meaningful to a £3m company. $5m utterly transformational. |
Posted at 14/11/2024 15:36 by tomboyb TCF had £2million pounds left at the end of March -They will need to raise very soon - |
Posted at 06/11/2024 09:01 by clocktower Well the Trump supporters and the markets seem euphorice this morning, and you never know TCF might soon benefit from the excitment in the market, and small pharma stocks may well become attractive once again.Only takes a bit of good news or a new deal and these sort of stocks fly, and become attractive because of the tax advantages in the UK. |
Posted at 07/8/2024 07:13 by peterm10 Im a big fan of sulforaphane, take a few supplements and there is a massive amount of supporting research out there. TCF have the only clinical grade tablet that must cost just pennies to produce and appears to work. Gotta keep believing ...what could possibly go wrong ....that hasn't already |
Posted at 19/7/2024 07:47 by clocktower Huge internet problems that appears not only to have effected airlines but to have hit a number of MM as there are fewer quotes this morning.I was considerting topping up with TCF this morning, as I feel something positive is going on, in light of the trades recently, but this outage is a problem it seems. Did anyone go to the AGM yesterday by the way and any comments? |
Posted at 04/6/2024 19:03 by terrydevlin1 Good luck Mark and CT. Whilst the Stalicla deal is still live I can’t see how this can go down much lower. But that deal looks to be on the rocks IMO. The fact TCF no longer mentioned up to $5.5m expected this year in the full results and Stalicla also removed from their website that this would go into phase 2 in 2024, it doesn’t look good. If the deal collapses this share price will be 0.1p and it’s game over. I question where is the money going to come from to bankroll this company? TCF needs between £3m and £4m a year which is enormous sums of money.I’ve been doing alright recently on the virtual dogs at the bookies, I’d rather stick a grand on a virtual dog than this dog of a share. |
Posted at 28/5/2024 16:15 by xxproinvestorxx Tcf FY26E is March 31st 2026. |
Posted at 28/5/2024 16:14 by xxproinvestorxx I didn't hear that in the presentation, however, when writing going concerns they can only report on what happened in the reported period, not after, except for the part that mentions post period. Also look at the research notes issued today, they also say cash into 2026. Say they expect TCF to "close FY26E with a closing cash balance of just under 0.3m" |
Posted at 26/5/2024 11:34 by terrydevlin1 I don’t know how anyone can think the results will be positive at all. Terrible 12 months here. No income, Juvenesense deal collapsed, Stalicla dispute, no new contracts signed, a share placing, money running out, next to no news on SFX-01 progressing. I think TCF may have a decent drug in SFX-01 buy they can’t afford to do any trials and can’t get anyone to trial it for them. Even if TCF get the $5.5m they hoped by the end of the year, where is the next income coming from? Stalicla payments clearly can’t be relied on. The end goal is already written here, another share placement which happens every 2 years is inevitable at some point. The shares will be diluted so much that there is no possibility of shareholders making any money here. There is no hope of TCF ever succeeding now. Don’t waste your time or money here. |
Posted at 10/5/2024 06:12 by terrydevlin1 I agree with your comment Clock Tower. It is incredibly disappointing to have no new deals signed up for SFX-01 since the Stalicla deal. There seems so little news now about SFX-01 in the past 10 months.The sad reality is that TCF cannot afford to do their own trials so they cannot do much to prove the drug is effective and it seems like they cannot get anyone to trial it for them. The Stalicla deal is so huge to TCF that they have no option but to wait for Stalicla to decide what they will do and when they will do it. It is TCF’s only potential income stream and money is running out. It is over a quarter of a year since the dispute was issued and no news at all. It doesn’t feel like there will be any news any time soon either. I feel for all investors who invested as a result of the Stalicla deal announcement in 2022. At that time with £10m in the bank, Juvenesense having a deal with SFX-01 and milestone payments of up to $160m with Stalicla it seemed like this share had great potential. I wish I never had stumbled on that RNS. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
